Skip to main content

Oligonucleotide Therapeutics: First Annual Meetingof the Oligonucleotide Therapeutics Society, Volume 1082

Oligonucleotide Therapeutics: First Annual Meetingof the Oligonucleotide Therapeutics Society, Volume 1082

Thomas Tuschl (Editor), John J. Rossi (Editor)

ISBN: 978-1-573-31587-6

Dec 2006, Wiley-Blackwell

300 pages

Select type: Paperback

In Stock

$154.95

Description

This volume concentrates on the most relevant oligonucleotide research and drug development areas and emphasizes the basic mechanisms and biology of oligonucleotide reagents.

Chapters are devoted to RNAi, oligonucleotide delivery, and immunomodulation. Because of the advanced stages of oligonucleotide-based drug development, preclinical and clinical data are also presented by leaders in the field.

NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas.

ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information about becoming a member

I. Delivery:.

1. Targeted Delivery of Antisense Oligonucleotide and Small Interference RNA into Lung Cancer Cells: Shyh-Dar Li.

2. Atelocollagen-Mediated Systemic DDS for Nucleic Acid Medicines: Koji Hanai.

3. Intracellular Delivery of Oligonucleotide Conjugates and Dendrimer Complexes: R.L. Juliano.

4. Mechanism of PNA Transport to the Nuclear Compartment: Lenka Stankova, Amy J. Ziemba, Zhanna V. Zhilina, and Scot W. Ebbinghaus.

II. Immunomodulation:.

5. The Concept of Immunostimulatory Nucleic Acids: CpG, the Plasmacytoid Dendritic Cell and Beyond: Gunther Hartmann.

6. Molecular Interaction of Toll-Like Receptor 9 and Nucleic Acid: Eicke Latz.

7. Effects of CpG ODN on Plasmacytoid Dendritic Cell-Induced Generation of Regulatory T Cells and Immune Tolerance: Wei Chen.

8. Induction of an Apoptotic Pathway in CLL Cells Stimulated by CpG ODN: George J. Weiner.

III. Identifying and Validating Targets and Systems:.

9. RNA Silencing in the Struggle Against Disease: Volker Patzel, Isabell Dietrich & Stefan H. E. Kaufmann.

10. shRNA as antiHIV Therapy: John J. Rossi.

11. Cellular Dynamics of Antisense Oligonucleotides and Short Interfering RNAs: Li Kim Lee, Brandee M. Dunham, Zhuting Li, and Charles M. Roth.

12. Inhibition of Hepatitis C IRES-mediated Gene Expression by Small Hairpin RNAs in Human Hepatocytes and Mice: Roger L. Kaspar, Qian Wang, Attila A. Seyhan, Heini Ilves, Alexander V. Vlassov, Christopher H. Contag, and Brian H. Johnston.

13. SiRNA-mediated Selective Inhibition of Mutant Keratin mRNAs Responsible for the Skin Disorder Pachyonychia Congenital: Robyn P. Hickerson, Frances J. D. Smith, W. H. Irwin McLean, Markus Landthaler, Rudolf Leube and Roger L. Kaspar.

14. Importance of Pharmacodynamic Studies- Discovering “Real” Mechanisms of Action: Cy A. Stein.

15. Multi-targeted Approach Using Antisense Oligonucleotides for the Treatment of Asthma: Z. Allakhverdia, M. Allama, A. Guimondb, N. Ferrari, K. Zemzoumib,.

R. Séguinb, L. Paquetb and P. M. Renzi.

16. Therapeutic Modulation of DMD Splicing by Blocking Exonic Splicing Enhancer Sites with Antisense Oligonucleotides: A. Aartsma-Rus, A.A.M. Janson, J.A. Heemskerk, C.L. de Winter, G-J.B. van Ommen and J.C.T. van Deutekom.

17. RNA- Targeted Suppression of Acetylcholinesterase: Hermona Soreq and Amir Dori.

18. Characterization of Antisense Oligonucleotides Comprised of 2’-deoxy-2’-fluoro-D-arabinonucleic Acid: Specificity, Potency and Duration of Activity: Nicolay Ferrari, Denis Bergeron, Anna-Lisa Tedeschi, Maria M. Mangos, Luc Paquet, Paolo M. Renzi and Masad J. Damha.

19. Anti-HIV Activity of Steric Block Oligonucleotides: Gabriela Ivanova, Andrey A. Arzumanov, John J. Turner, Sandrine Reigadas, Jean-Jacques Toulme, Douglas E. Brown, Andrew M.L. Lever and Michael J. Gait.

20. Selection of Thioaptamers for Diagnostics and Therapeutics: Xianbin Yang, He Wang, David W. C. Beasley, David E. Volk, Xu Zhao, Bruce A. Luxon, Lee O. Lomas, Norbert Herzog, Judith F. Aronson, Alan D. T. Barrett, James F. Leary, and David G. Gorenstein.

21. Small Fragment Homologous Replacement – mediated Modification of The PIG CFTR GENE: Rosalie Maurisse1, Judy Cheung, Jonathan Widdicombe, Dieter C. Gruenert.

IV. Clinical Studies:.

22. Neucleic Acids for Treating Leukemia and Lymphoma: Alan M. Gewirtz.

23. Clinical Development of B-and C-Class CpG ODN: In Vivo Modulation of Plasmacytoid Dendric Cell Function by Regulating ODN Secondary Structure: Arthur M. Kreig.

24. CpG Oligonucleotides Improve the Protective Immune Response Induced by the Licensed Anthrax Vaccine: Dennis M. Klinman, Hang Xie, Bruce E. Ivins,.

25. CpG Oligonucleotides Improve the Protective Immune Response Induced by the Licensed Anthrax Vaccine: Dennis M. Klinman.

26. Anti-VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular Diseases: Eugene W. M. Ng and Anthony P. Adamis